Shares of Dyax Corp. (NasdaqGS: DYAX) surged nearly 50% during Tuesday’s after-hours session after the Massachusetts-based company said an early stage trial of its treatment for hereditary angioedema proved safe for use and effective in reducing extreme swelling attacks. Dyax also announced receipt...